How can we prevent multisystem complications of cystic fibrosis?

被引:13
作者
Elborn, J. Stuart
机构
[1] QUB, Resp Med Grp, Belfast, Antrim, North Ireland
[2] BCH, No Ireland Adult Cyst Fibrosis Ctr, Belfast, Antrim, North Ireland
关键词
cystic fibrosis; inflammation; osteoporosis; diabetes; liver disease;
D O I
10.1055/s-2007-981651
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Cystic fibrosis (CF) is a multisystem disease. Some of this is accounted for by CF transmembrane regulator (CFTR) dysfunction in individual organs but in some cases this is compounded by the effects of systemic inflammation. The inflammation is in response to the chronic infection in the airways and is particularly important as a contributor to CF-related bone disease, CF-related diabetes mellitus, CF-related arthropathy, and vasculitis. Preventing these multisystem complications is difficult. Aggressive specific therapies to treat complications is critically important to maintain nutrition, stop the damaging effects of diabetes, and improve bone mineral density. Aggressive treatment of lung disease to reduce systemic inflammation is likely to be of benefit in preventing the development of CF-related bone disease and may be beneficial in at least delaying the onset of CF-related diabetes. Aggressive treatment of pulmonary infection and inflammation in conjunction with holistic management plans to treat specific organ diseases is an important strategy in improving morbidity and reducing mortality in people with CF.
引用
收藏
页码:303 / 311
页数:9
相关论文
共 84 条
[1]   Perceived body image and eating behavior in young adults with cystic fibrosis and their healthy peers [J].
Abbott, J ;
Conway, S ;
Etherington, C ;
Fitzjohn, J ;
Gee, L ;
Morton, A ;
Musson, H ;
Webb, AK .
JOURNAL OF BEHAVIORAL MEDICINE, 2000, 23 (06) :501-517
[2]   Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas [J].
Ahmed, N ;
Corey, M ;
Forstner, G ;
Zielenski, J ;
Tsui, LC ;
Ellis, L ;
Tullis, E ;
Durie, P .
GUT, 2003, 52 (08) :1159-1164
[3]  
[Anonymous], COCHRANE DATABASE SY
[4]  
[Anonymous], NUTR MAN CYST FIBR
[5]   Etanercept for refractory asthma therapy [J].
Antoniu, Sabina A. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (10) :1279-1281
[6]   Efficacy of alendronate in adults with cystic fibrosis with low bone density [J].
Aris, RM ;
Lester, GE ;
Caminiti, M ;
Blackwood, AD ;
Hensler, M ;
Lark, RK ;
Hecker, TM ;
Renner, JB ;
Guillen, U ;
Brown, SA ;
Neuringer, IP ;
Chalermskulrat, W ;
Ontjes, DA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (01) :77-82
[7]   Consensus statement: Guide to bone health and disease in cystic fibrosis [J].
Aris, RM ;
Merkel, PA ;
Bachrach, LK ;
Borowitz, DS ;
Boyle, MP ;
Elkin, SL ;
Guise, TA ;
Hardin, DS ;
Haworth, CS ;
Holick, MF ;
Joseph, PM ;
O'Brien, K ;
Tullis, E ;
Watts, NB ;
White, TB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1888-1896
[8]   Carboxylated osteocalcin levels in cystic fibrosis [J].
Aris, RM ;
Ontjes, DA ;
Brown, SA ;
Chalermskulrat, W ;
Neuringer, I ;
Lester, GE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (09) :1129-1129
[9]   Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis [J].
Aris, RM ;
Stephens, AR ;
Ontjes, DA ;
Blackwood, AD ;
Lark, RK ;
Hensler, MB ;
Neuringer, IP ;
Lester, GE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (05) :1674-1678
[10]   Antioxidant deficiency in cystic fibrosis: when is the right time to take action? [J].
Back, EI ;
Frindt, C ;
Nohr, D ;
Frank, J ;
Ziebach, R ;
Stern, M ;
Ranke, M ;
Biesalski, HK .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2004, 80 (02) :374-384